NJ Bio, Inc. is excited to announce its strategic partnership with Suven Pharmaceuticals, a leading CDMO based in Hyderabad, India. Suven, backed by Boston-based private equity firm Advent International, has acquired a 56% equity stake in NJ Bio through a $64.4 million transaction, which was completed on December 28, 2024.This includes a $15 million primary equity infusion aimed at accelerating NJ Bio’s growth initiatives, alongside a secondary acquisition.
This investment marks a significant milestone for both companies, combining Suven’s expertise in technology driven CDMO services with NJ Bio’s leadership in ADCs and other targeted therapeutics. The acquisition highlights Suven Pharma’s strategic focus on biopharmaceuticals and its aim to expand its presence in the high-growth global ADC market. The capital infusion will support NJ Bio’s continued growth, particularly in the development of its GMP manufacturing suites in Princeton, enhancing its ability to provide end-to-end ADC services from early-stage development to commercial-scale manufacturing.
This partnership represents a transformative step for NJ Bio. With Suven’s support, the company looks forward to expanding its capabilities and strengthening its commitment towards advancing ADC therapies globally.
For more details about this acquisition visit https://www.suvenpharm.com/pdf/Investors/ShareHoldersInfo/statutory-communications/Suvenpharm_pr_ip.pdf